Concepedia

Lucinda Shepherd

LS

Statistics

Publications

3

Citations

3.9K

H-Index

3

Active since

1995

Affiliations

Istanbul University-Cerrahpaşa(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Lucinda Shepherd is an author at Istanbul University-Cerrahpaşa specializing in medicine, radiation oncology, and oncology.

Top concepts

Publications per year

1995–2021

3

Publications

3

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

, , +7

Palliative radiation for stage 3 non-small cell lung cancer — A prospective study of two moderately high dose regimens

Raymond P. Abratt, Lucinda Shepherd, D.G.M. Salton · Lung Cancer · 1995 · 84 citations

, , +9

Rows per page

1–3 of 3